Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;8(Suppl 4):S378-S382.
doi: 10.21037/tlcr.2019.04.15.

Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option

Biagio Ricciuti  1 , Giuseppe Lamberti  2 , Fausto Roila  1 , Giulio Metro  1
Affiliations
Editorial

Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option

Biagio Ricciuti et al. Transl Lung Cancer Res. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flow chart of the ALK Master Protocol. ALK, anaplastic lymphoma kinase; FDA, Food and Drug Administration; NSCLC, non-small-cell lung cancers; TKI, tyrosine kinase-inhibitor; PS, performance status.
See this image and copyright information in PMC

Comment on

  • Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
    Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Camidge DR, et al. N Engl J Med. 2018 Nov 22;379(21):2027-2039. doi: 10.1056/NEJMoa1810171. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280657 Clinical Trial.

References

    1. Metro G, Bellezza G, Puma F, et al. How might treatment of ALK-positive non-small cell lung cancer change in the near future? Expert Rev Anticancer Ther 2016;16:997-9. 10.1080/14737140.2016.1226138 - DOI - PubMed
    1. Metro G, Tazza M, Matocci R, et al. Optimal management of ALK-positive NSCLC progressing on crizotinib. Lung Cancer 2017;106:58-66. 10.1016/j.lungcan.2017.02.003 - DOI - PubMed
    1. Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov 2017;7:137-55. 10.1158/2159-8290.CD-16-1123 - DOI - PMC - PubMed
    1. Ali R, Arshad J, Palacio S, et al. Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy. Drug Des Devel Ther 2019;13:569-80. 10.2147/DDDT.S147499 - DOI - PMC - PubMed
    1. Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol 2017;35:2490-8. 10.1200/JCO.2016.71.5904 - DOI - PubMed